
AAD 2023 – Takeda outdoes Bristol’s Sotyktu
TAK-279 comes out on top in the battle of the Tyk2 inhibitors, but biologicals still rule.

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.

World ADC 2023 – targeting the folate receptor rises from the ashes
Zymeworks, Profoundbio, Elucida and Immunogen itself piggyback on Elahere’s success to develop a better antibody-drug conjugate.

ACC 2023 – Merck’s oral cholesterol lowerer shows mid-stage promise
The oral PCSK9 project MK-0616 meets its targets in phase 2, which could be bad news for Novartis.

ACC 2023 – Merck reaches for the stars
The Stellar trial of sotatercept lives up to its name, but the asset did not come cheap.

ACC 2023 – Esperion’s outcomes win looks lacklustre
A 13% reduction in the risk of cardiovascular events is statistically significant but not spectacular.

CROI 2023 – GSK and Gilead’s long-acting HIV battle intensifies
GSK shows that Cabenuva every two months is as good as daily Biktarvy, but Gilead looks to go even longer.